Check out the online preprint on our work defining #SARSCoV2 T-cell epitopes SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition researchsquare.com/article/rs-353…

Können frühere Erkältungen gegen #Covid_19 schützen?🤔Das Forscherteam um Dr. Juliane Walz zeigt, wie das #Immunsystem aus bereits überstandenen Infektionen lernt und sich anpasst. #uniklinikumtuebingen #Coronavirus #TZellen # Peptide-based Immunotherapy

Check out this short german TV coverage on our #SARS_CoV_2 peptide #vaccine by 3sat 3sat.de/wissen/nano/20…

Der Wissenschaftler der Uni Tübingen wird mit dem Landesforschungspreis 2020 ausgezeichnet, der mit 100.000 Euro dotiert ist. tagblatt.de/Nachrichten/Ni…

Very happy and excited that one of our publications is among the 5 most popular scientific papers in the Nature Index journals #sciencetwitter #SARS_CoV_2

Check out our latest review "The peptide #vaccine of the future" by Annika Nel published in Molecular & Cellular Proteomics mcponline.org/content/mcprot… mcponline.org/content/early/…

We are starting a phase-I #clinicaltrial for our peptide #vaccine against chronic lymphocytic leukemia (CLL). The aim is to avoid relapse due to minimal residual disease after first line therapy with Ibrutinib. Uniklinikum Tübingen medizin.uni-tuebingen.de/de/das-kliniku…

Check out the article from the local newspaper Tagblatt Redaktion tagblatt.de/Nachrichten/Th…

Check out our latest preprint: This first comprehensive analysis of #SARS_CoV_2 immune responses in #cancer patients reports on the implications of impaired SARS-CoV-2 T cell responses for understanding pathophysiology and predicting severity of #COVID19 researchsquare.com/article/rs-237…

Very proud that Juliane Walz received this years best abstract award at the DGHO e. V. for her presentation on our peptide-based #COVID19 #vaccine for patients affected by antibody shortage

Two exciting talks were held by our lab members @mroerden1 and Jens Bauer on #Covid_19 #tcell responses in #Cancer patients and a new fusion protein as potential immunotherapeutic target for the treatment of FLHCC at this years DGHO e. V. meeting

We conducted a phase I #clinicaltrial with CoVac-1, our #peptide-based #COVID19 #vaccine candidate for induction of SARS-CoV-2 T cell immunity. Our observations support the presently ongoing phase II trial for patients with B cell/antibody deficiency. Here’s what we found: